|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1999-4-13
|
|
pubmed:abstractText |
Previous studies have shown that substitution of single amino acid residues in human Melan-A immunodominant peptides Melan-A27-35 and Melan-A26-35 greatly improved their binding and the stability of peptide/HLA-A*0201 complexes. In particular, one Melan-A peptide analogue was more efficient in the generation of Melan-A peptide-specific and melanoma-reactive CTL than its parental peptide in vitro from human PBL. In this study, we analyzed the in vivo immunogenicity of Melan-A natural peptides and their analogues in HLA-A*0201/Kb transgenic mice. We found that two human Melan-A natural peptides, Melan-A26-35 and Melan-A27-35, were relatively weak immunogens, whereas several Melan-A peptide analogues were potent immunogens for in vivo CTL priming. In addition, induced Melan-A peptide-specific mouse CTL cross-recognized natural Melan-A peptides and their analogues. More interestingly, these mouse CTL were also able to lyse human melanoma cell lines in vitro in a HLA-A*0201-restricted, Melan-A-specific manner. Our results indicate that the HLA-A*0201/Kb transgenic mouse is a useful animal model to perform preclinical testing of potential cancer vaccines, and that Melan-A peptide analogues are attractive candidates for melanoma immunotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Arginine,
http://linkedlifedata.com/resource/pubmed/chemical/Epitopes, T-Lymphocyte,
http://linkedlifedata.com/resource/pubmed/chemical/H-2 Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/H-2Kb protein, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-A Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Leucine,
http://linkedlifedata.com/resource/pubmed/chemical/MART-1 Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/MLANA protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Mlana protein, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Oligopeptides
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0022-1767
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
162
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3566-73
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:10092815-Alleles,
pubmed-meshheading:10092815-Animals,
pubmed-meshheading:10092815-Antigens, Neoplasm,
pubmed-meshheading:10092815-Arginine,
pubmed-meshheading:10092815-Cell Line,
pubmed-meshheading:10092815-Cytotoxicity, Immunologic,
pubmed-meshheading:10092815-Epitopes, T-Lymphocyte,
pubmed-meshheading:10092815-H-2 Antigens,
pubmed-meshheading:10092815-HLA-A Antigens,
pubmed-meshheading:10092815-Humans,
pubmed-meshheading:10092815-Injections, Subcutaneous,
pubmed-meshheading:10092815-Leucine,
pubmed-meshheading:10092815-Lymphocyte Activation,
pubmed-meshheading:10092815-MART-1 Antigen,
pubmed-meshheading:10092815-Melanoma,
pubmed-meshheading:10092815-Mice,
pubmed-meshheading:10092815-Mice, Transgenic,
pubmed-meshheading:10092815-Neoplasm Proteins,
pubmed-meshheading:10092815-Oligopeptides,
pubmed-meshheading:10092815-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:10092815-T-Lymphocytes, Helper-Inducer,
pubmed-meshheading:10092815-Tumor Cells, Cultured
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Assessment of immunogenicity of human Melan-A peptide analogues in HLA-A*0201/Kb transgenic mice.
|
|
pubmed:affiliation |
Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, Switzerland.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
